Snipr Biome chose clinical debut in CRISPR-ready USA

Danish CRISPR company Snipr Biome is betting on the US following the FDA's thumbs-up to begin phase I clinical testing of its first drug candidate, says CEO Christian Grøndahl, who is in final talks with two US-based contractors for the trial.
Christian Grøndahl, CEO at Snipr Biome | Photo: Snipr Biome/PR
Christian Grøndahl, CEO at Snipr Biome | Photo: Snipr Biome/PR
by ULRICH QUISTGAARD, translated by daniel pedersen

Snipr Biome has great expectations for 2022 following the US Food and Drug Administration (FDA) approval of the company's application to initiate a phase I clinical trial with its first development candidate, which will be conducted in the US.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading